

applicant's  
copy  
Sheet 1 of 8

FORM PTOL 449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.  
P1726R1P1

Serial No.  
09/713,425

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
Presta, L.

Filing Date

15 Nov 2000

15 Nov 2000

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
DCL	1 4,752,601	21.06.88	Hahn	—	—	—
	2 5,348,876	20.09.94	Michaelson et al.	—	—	—
	3 5,624,821	29.04.97	Winter et al.	—	—	—
	4 5,648,260	15.07.97	Winter et al.	—	—	—
	5 5,698,449	15.12.97	Baumann et al.	—	—	—
	6 5,736,137	07.04.98	Anderson et al.	—	—	—
	7 5,935,599	16.11.99	McKenzie et al.	—	—	—
	8 6,194,551 B1	27.02.01	Idusogie et al.	—	—	—

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
DCL ↓	9	WO 60/09560	24.02.00	PCT	11	11		
	10	WO 88/07089	22.09.88	PCT	11	11		
	11	WO 94/29351	22.12.94	PCT	11	11		
	12	WO 97/28267	07.08.97	PCT	11	11		
	13	WO 97/44362	27.11.97	PCT	11	11		
	14	WO 98/23289	04.06.98	PCT	11	11		
	15	WO 98/52975	26.11.98	PCT	11	11		
	16	WO 99/43713	02.09.99	PCT	11	11		
	17	WO 99/51642	14.10.99	PCT	11	11		
	18	WO 99/58572	18.11.99	PCT	11	11		

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

DCL	19	Allan and Isliker, "Studies on the complement-binding site of rabbit immunoglobulin G-1. Modification of tryptophan residues and their role in anticomplementary activity of rabbit IgG" <u>Immunochimistry</u> 11(4):175-180 (Apr 1974)
	20	Anga et al., "A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody" <u>Molecular Immunology</u> 30(1):105-108 (Jan 1993)
	21	Armour et al., "Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities" <u>European Journal of Immunology</u> 29(8):2613-2624 (Aug 1999)
	22	Bloom et al., "Intrachain disulfide bond in the core hinge region of human IgG4" <u>Protein Science</u> 6:407-415 (1997)
	23	Bolland et al., "SHIP modulates immune receptor responses by regulating membrane association of Btk" <u>Immunity</u> 8(4):509-516 (Apr 1998)
	24	Bredius et al., "Role of neutrophil FcγRIIa (CD32) and FcγRIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes" <u>Immunology</u> 83(4):624-630 (Dec 1994)
	25	Brekke et al., "Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis" <u>European Journal of Immunology</u> 24(10):2542-2547 (Oct 1994)
	26	Burmeister et al., "Crystal structure of the complex of rat neonatal Fc receptor with Fc" <u>Nature</u> 372(6504):379-383 (Nov 24, 1994)

Examiner

David A. Lerman

Date Considered

6/7/04

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1726R1P1

Serial No.

09/713,025

Applicant

Presta, L.

Filing Date

1<sup>st</sup> Nov 2000

Group

053

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

27	Burton and Woof, "Human Antibody Effector Function" <u>Advances in Immunology</u> 51:1-84 (1992)
28	Burton et al., "Molecular recognition of antibody (IgG) by cellular Fc receptor (FcR1)" <u>Molecular Immunology</u> 25(11):1175-1181 (1988)
29	Burton et al., "The Clq receptor site on Immunoglobulin G" <u>Nature</u> 288(5789):338-344 (Nov 27, 1980)
30	Burton, D.R., "Immunoglobulin G: Functional Sites" <u>Molecular Immunology</u> 22(3):161-206 (1985)
31	Canfield and Morrison, "The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region" <u>Journal of Experimental Medicine</u> 173(6):1483-1491 (Jun 1, 1991)
32	Capel et al., "Heterogeneity of Human IgG Fc Receptors" <u>Immunomethods</u> 4:25-34 (1994)
33	Capon et al., "Designing CD4 Immunoadhesins for AIDS Therapy" <u>Nature</u> 337:525-531 (February 9, 1989)
34	Carter et al., "Humanization of an anti-p185HER2 antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci. USA</u> 89:4285-4289 (1992)
35	Chappel et al., "Identification of Secondary FcγRI Binding Site within a Genetically Engineered Human IgG Antibody" <u>Journal of Biological Chemistry</u> 268:25124-25131 (1993)
36	Chappel et al., "Identification of the Fcγ receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 88(20):9036-9040 (Oct 15, 1991)
37	Clynes and Ravetch, "Cytotoxic antibodies trigger inflammation through Fc receptors" <u>Immunity</u> 3(1):21-26 (Jul 1995)
38	Clynes et al., "Fc receptors are required in passive and active immunity to melanoma" <u>Proc. Natl. Acad. Sci. USA</u> 95(2):652-656 (Jan 20, 1998)
39	Clynes et al., "Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors" <u>Journal of Experimental Medicine</u> 189(1):179-185 (Jan 4, 1999)
40	Clynes et al., "Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis" <u>Science</u> 279(5353):1052-1054 (Feb 13, 1998)
41	Cosimi, A.B., "Clinical Development of ORTHOCLONE OKT3" <u>Transplantation Proceedings</u> (Suppl 1) XIX(2):7-16 (Apr 1987)
42	Daeron, M., "Fc Receptor Biology" <u>Annual Review of Immunology</u> 15:203-234 (1997)
43	de Haas et al., "Fcγ receptors of phagocytes" <u>J. of Laboratory Clinical Medicine</u> 126:330-341 (1995)
44	Deisenhofer, J., "Crystallographic Refinement and Atomic Models of a Human Fc fragment and Its Complex with Fragment B of Protein A from Staphylococcus aureus at 2.9- and 2.8-Å Resolution" <u>Biochemistry</u> 20(9):2361-2370 (1981)
45	Duncan and Winter, "The binding site for Clq on IgG" <u>Nature</u> 332:738-740 (Apr 21, 1988)
46	Duncan et al., "Localization of the binding site for the human high-affinity Fc receptor on IgG" <u>Nature</u> 332:563-564 (April 7, 1988)

Examiner

David A. Saunders

Date Considered

6/7/04

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

MAR 23 2001

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1726R1P1

Serial No.

09/71,745

Applicant

Presta, L.

Filing Date

15 Nov 2000

Group

1653

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- 47 Gazzano-Santoro et al., "A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody" Journal of Immunological Methods 202:163-171 (1997)
- 48 Gergely et al., "Fc receptors on lymphocytes and K cells" Biochemical Society Transactions 12(5):739-743 (Oct 1984)
- 49 Ghebreniwet et al., "Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1q" Journal of Experimental Medicine 179(6):1809-1821 (Jun 1, 1994)
- 50 Ghetie and Ward, "FcRn: the MHC class I-related receptor that is more than an IgG transporter" Immunology Today 18(12):592-593 (Dec 1997)
- 51 Ghetie et al., "Abnormally short serum half lives of IgG in  $\beta$ 2-microglobulin-deficient mice" European Journal of Immunology 26(3):690-696 (Mar 1996)
- 52 Ghetie et al., "Increasing the serum persistence of an IgG fragment by random mutagenesis" Nature Biotechnology 15(7):637-640 (Jul 1997)
- 53 Gorman et al., "Transient Production of Proteins Using an Adenovirus Transformed Cell Line" DNA Prot. Eng. Tech. 2(1):3-10 (1990)
- 54 Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5" J. Gen. Virol. 36:59-74 (1977)
- 55 Greenwood et al., "Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis" Therapeutic Immunology 1(5):247-255 (Oct 1994)
- 56 Greenwood et al., "Structural motifs involved in human IgG antibody effector functions" European Journal of Immunology 23(5):1098-1104 (May 1993)
- 57 Guddat et al., "Three-dimensional structure of a human immunoglobulin with a hinge deletion" PNAS (USA) 90:4271-4275 (1993)
- 58 Haagen et al., "Interaction of Human Monocyte Fc $\gamma$  Receptors with Rat IgG2b: A New Indicator for the Fc $\gamma$ RIIa (R H131) Polymorphism" J. Immunol. 154:1852-1860 (1995)
- 59 Hadley et al., "The functional activity of Fc $\gamma$ RII and Fc $\gamma$ RIII on subsets of human lymphocytes" Immunology 75(3):446-451 (Jul 1992)
- 60 Harris et al., "Crystallographic Structure of an Intact IgG1 Monoclonal Antibody" Journal of Molecular Biology 275:361-372 (1998)
- 61 Harris et al., "Refined Structure of an Intact IgG2a Monoclonal Antibody" Biochemistry 36:1581-1597 (1997)
- 62 Hatta et al., "Association of Fc $\gamma$  receptor IIIB, but not of Fc $\gamma$  receptor IIA and IIIB, polymorphisms with systemic lupus erythematosus in Japanese" Genes and Immunity 1:53-60 (1999)
- 63 Heiken et al., "T lymphocyte development in the absence of Fc $\epsilon$  receptor  $\gamma$  subunit: analysis of thymic-dependent and independent  $\alpha\beta$  and  $\gamma\delta$  pathways" European Journal of Immunology 26(8):1935-1943 (Aug 1996)
- 64 Henry et al., "Participation of the N-terminal region of C $\epsilon$ 3 in the binding of human IgE to its high-affinity receptor Fc $\epsilon$ RI" Biochemistry 36:15568-15578 (1997)
- 65 Hogarth et al., "Characterization of Fc $\epsilon$  Ig-binding sites and epitope mapping" Immunomethods 4(1):17-24 (Feb 1994)
- 66 Huizinga et al., "Binding Characteristics of Dimeric IgG Subclass Complexes to Human Neutrophils" Journal of Immunology 142:2359-2364 (1989)

Examiner

*David A. Saunders*

Date Considered

*6/7/04*

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

MAR 23 2001

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1726R1P1

Serial No.

P1726R1P1

Applicant

Presta, L.

Filing Date

15 Nov 2000

Group

1

## LIST OF DISCLOSURES MADE BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- 67 Hulett et al., "Chimeric Fc Receptors Identify Functional Domains of the Murine High Affinity Receptors for IgG" J. Immunol. 147:1863-1868 (1991)
- 68 Jaakkola et al., "In vivo detection of vascular adhesion protein-1 in experimental inflammation" American Journal of Pathology 157(2):463-471 (Aug 2000)
- 69 Jareway et al. Immunobiology, The Immune System in Health and Disease, CB Ltd and Garland Publishing Inc., NY & London (1994), PAGES 3:29-3:30.
- 70 Jefferis et al., "Molecular Definition of Interaction Sites on Human IgG for Fc Receptors (huFcγR)" Molecular Immunology 27(12):1237-1240 (1990)
- 71 ~~Fabat. Sequences of Proteins of Immunological Interest, US Dept of Health and Human Services, NIH, 5th edition, Bethesda, MD (1991)~~
- 72 Fabat, E. et al. Sequences of Proteins of Immunological Interest (pgs. 569, 671, 687, 695), 5th edition, Bethesda, MD:NIH Vol. 1 (1991)
- 73 Kim et al., "Catabolism of the Murine IgG1 Molecule: Evidence That Both CH2-CH3 Domain Interfaces are Required for Persistence of IgG1 in the Circulation of Mice" Scandinavian Journal Of Immunology 40(4):457-465 (1994)
- 74 Kim et al., "Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis" European Journal of Immunology 24:542-548 (1994)
- 75 Kim et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in vivo" Nature 362:841-844 (1993)
- 76 Kim et al., "Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor" European Journal of Immunology 24:2429-2434 (1994)
- 77 Kim et al., "The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies" Growth Factors 7(1):53-64 (1992)
- 78 Koene et al., "FcγRIIIa-158V/F Polymorphism Influences the Binding of the IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype" Blood 90(3):1109-1114 (1997)
- 79 Funkel, T., "Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic Selection" Proc. Natl. Acad. Sci. 82:488-492 (1985)
- 80 Lauvrak et al., "Identification and characterisation of Clq-binding phage displayed peptides" Biological Chemistry 378(12):1509-1519 (Dec 1997)
- 81 Lehnbecher et al., "Variant genotypes of FcγRIIIa influence the development of Kaposi's sarcoma in HIV-infected men" Blood 95(7):2386-2390 (2000)
- 82 Lehnbecher et al., "Variant genotypes of the low-affinity Fcγ receptors in two control populations and a review of low-affinity Fcγ receptor polymorphisms in control and disease populations" Blood 94(12):4220-4232 (Dec 15, 1999)
- 83 Li et al., "Reconstitution of human FcγRIII cell type specificity in transgenic mice" Journal of Experimental Medicine 183(3):1259-1263 (Mar 1, 1996)
- 84 Lively et al., "Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions" Glycobiology 5(8):813-822 (Dec 1995)
- 85 Lorenz et al., "Strong association between the responder status of the FcγII receptor and recurrent spontaneous abortion" European Journal of Immunogenetics 22(5):397-401 (Oct 1995)
- 86 Lucas et al., "High-level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector" Nucleic Acids Research 24(9):1774-1779 (1996)

Examiner

Dana A. Saunders

Date Considered

6/7/04

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1726R1P1

Sheet 5 of 8

Serial No.

09/78, 425

Applicant

Presta, L.

Filing Date

15 Nov 2000

Group

165

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- 87 Lund et al., "Human FcγRI and FcγRII interact with distinct but overlapping sites on human IgG" Journal of Immunology 147(8):2657-2662 (Oct 15, 1991)
- 88 Lund et al., "Multiple binding sites on the CH2 domain of IgG for mouse FcγRII" Molecular Immunology 29(1):53-59 (Jan 1992)
- 89 Lund et al., "Multiple Interactions of the IgG with Its Core Oligosaccharide Can Modulate Recognition by Complement and Human Fcγ Receptor I and Influence the Synthesis of Its Oligosaccharide Chains" J. Immunol. 157:4963-4969 (1996)
- 90 Lund et al., "Oligosaccharide-protein interactions in IgG can modulate recognition by Fcγ receptors" FASEB Journal 9:115-119 (1995)
- 91 Medesan et al., "Comparative studies of rat IgG to further delineate the Fc:FcRn interaction site" European Journal of Immunology 28:2092-2100 (1998)
- 92 Medesan et al., "Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1" Journal of Immunology 158(5):2211-2217 (Mar 1, 1997)
- 93 Medesan et al., "Localization of the site of the IgG molecule that regulates maternal-fetal transmission in mice" European Journal of Immunology 26(10):2533-2536 (Oct 1996)
- 94 Meng et al., "Green fluorescent protein as a second selectable marker for selection of high producing clones from transfected CHO cells" Gene 242:201-207 (2000)
- 95 Miller et al., "A Novel Role for the Fc Receptor γ Subunit: Enhancement of the FcγR Ligand Affinity" Journal of Experimental Medicine 183:2227-2233 (1996)
- 96 Morgan et al., "The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, FcγRI and FcγRIII binding" Immunology 86(2):319-324 (Oct 1995)
- 97 Morrison et al., "Structural Determinants of Human IgG Function" Immunologist 2:119-124 (1994)
- 98 Nagarajan et al., "Ligand binding and phagocytosis by CD16 (Fc γ receptor III) isoforms. Phagocytic signaling by associated ζ and γ subunits in Chinese hamster ovary cells" Journal of Biological Chemistry 270(43):25762-25770 (Oct 27, 1995)
- 99 Ngo et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox" The Protein Folding Problem and Tertiary Structure Prediction, Merz & Le Grand, Boston: Birkhauser pps. 491-495 (1994)
- 100 Nieto et al., "Involvement of the Fcγ receptor IIIA genotypes in susceptibility to rheumatoid arthritis" Arthritis and Rheumatism 43(4):735-739 (2000)
- 101 Okada et al., "Cutting Edge: Role of the inositol phosphatase SHIP in B cell receptor-induced Ca<sup>2+</sup> oscillatory response" Journal of Immunology 161(10):5129-5132 (Nov 15, 1998)
- 102 Ono et al., "Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling" Cell 90(2):293-301 (Jul 25, 1997)
- 103 Ono et al., "Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FcγRIIb" Nature 383(6597):263-266 (Sep 19, 1996)
- 104 Papac et al., "A high-throughput microscale method to release N-linked oligosaccharide from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis" Glycobiology 8(5):445-454 (1998)
- 105 Papac et al., "Analysis of Acidic Oligosaccharides and Glycopeptides by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry" Anal. Chem. 68:3215-3223 (1996)
- 106 Popov et al., "The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn" Molecular Immunology 33(6):521-530 (Apr 1996)

Examiner

*David S. Summers*

Date Considered

6/7/04

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1726R1P1

Serial No.

09/7/93 25

Applicant

Presta, L.

Filing Date

15 Nov 2000

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

107	Porges et al., "Novel Fcγ Receptor I Family Gene Products in Human Mononuclear Cells" <u>J. Clin. Invest.</u> 90:2102-2109 (1992)
108	Presta et al., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders" <u>Cancer Research</u> 57(20):4593-4599 (Oct 15, 1997)
109	Raghavan and Bjorkman, "Fc Receptors and their Interactions with Immunoglobulins" <u>Annu. Rev. Cell. Dev. Biol.</u> 12:181-220 (1996)
110	Raghavan et al., "Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants" <u>Biochemistry</u> 34(45):14649-14657 (Nov 14, 1995)
111	Favetch and Clynes, "Divergent roles for Fc receptors and complement in vivo" <u>Annual Review of Immunology</u> 16:421-432 (1998)
112	Favetch and Kinet, "Fc Receptors" <u>Annual Review of Immunology</u> 9:457-492 (1991)
113	Favetch, J., "Fc receptors" <u>Current Opinion in Immunology</u> 9(1):121-125 (Feb 1997)
114	Favetch, J., "Fc receptors: rubor redux" <u>Cell</u> 78(4):555-560 (Aug 26, 1994)
115	Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20" <u>Blood</u> 83(2):435-445 (Jan 15, 1994)
116	Sarmay et al., "Ligand inhibition studies on the role of Fc receptors in antibody-dependent cell-mediated cytotoxicity" <u>Molecular Immunology</u> 21(1):43-51 (Jan 1984)
117	Sarmay et al., "Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fcγ receptor" <u>Molecular Immunology</u> 29(5):633-639 (May 1992)
118	Sensel et al., "Amino acid differences in the N-terminus of Cγ2 influence the relative abilities of IgG2 and IgG3 to activate complement" <u>Molecular Immunology</u> 34(14):1019-1029 (Oct 1997)
119	Shores et al., "T cell development in mice lacking all T cell receptor ζ family members (ζ, η, and FcεRIγ)" <u>Journal of Experimental Medicine</u> 187(7):1093-1101 (Apr 6, 1998)
120	Sondermann et al., "Crystal structure of the soluble form of the human Fcγ-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 Å resolution" <u>EMBO Journal</u> 18(5):1095-1103 (1999)
121	Sondermann et al., "The 32-Å crystal structure of the human IgG1 Fc Fragment-FcγRIII complex" <u>Nature</u> 406:267-273 (2000)
122	Strohmeier et al., "Neutrophil functional responses depend on immune complex valency" <u>Journal of Leukocyte Biology</u> 58(4):403-414 (Oct 1995)
123	Strohmeier et al., "Role of the FcγR subclasses FcγRII and FcγRIII in the activation of human neutrophils by low and high valency immune complexes" <u>Journal of Leukocyte Biology</u> 58(4):415-422 (Oct 1995)
124	Suzuki et al., "Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis" <u>Kidney International</u> 54(4):1166-1174 (Oct 1998)
125	Sylvestre and Favetch, "A dominant role for mast cell Fc receptors in the Arthus reaction" <u>Immunity</u> 5(4):387-390 (Oct 1996)
126	Sylvestre and Favetch, "Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade" <u>Science</u> 265(5175):1095-1098 (Aug 19, 1994)

Examiner

*David A. Saunders*

Date Considered

*6/7/07*

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1726RIP

Serial No.

09,713,425

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- 127 Sylvestre et al., "Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice" Journal of Experimental Medicine 184(6):2385-2392 (Dec 1, 1996)
- 128 Takai et al., "Augmented humoral and anaphylactic responses in FcγII-deficient mice" Nature 379(6563):346-349 (Jan 25, 1996)
- 129 Takai et al., "Fcγ chain deletion results in pleiotrophic effector cell defects" Cell 76(3):519-529 (Feb 11, 1994)
- 130 Panm et al., "The IgG binding site of human FcγRIIIB receptor involves CC' and FG loops of the membrane-proximal domain" Journal of Biological Chemistry 271(7):3659-3666 (Feb 16, 1996)
- 131 Tao et al., "Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation" Journal of Experimental Medicine 178(2):661-667 (Aug 1, 1993)
- 132 Tao et al., "Studies of aglycosylated chimeric mouse-human IgG. Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region" Journal of Immunology 143(8):2595-2601 (Oct 15, 1989)
- 133 Tao et al., "The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the C<sub>H</sub>2 domain" Journal of Experimental Medicine 173(4):1025-1028 (Apr 1991)
- 134 Tax et al., "Fc receptors for mouse IgG<sub>1</sub> on human monocytes: polymorphism and role in antibody-induced T cell proliferation" Journal of Immunology 133(3):1185-1189 (Sep 1984)
- 135 Ting et al., "Fcγ Receptor activation induces the tyrosine phosphorylation of both phospholipase C (PLC)-γ1 and PLC-γ2 in natural killer cells" Journal of Experimental Medicine 176(6):1751-1755 (Dec 1, 1992)
- 136 Umara et al., "Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity" Nature Biotechnology 17:176-180 (1999)
- 137 Urfer et al., "High resolution mapping of the binding site of TrkA for nerve growth factor and TrkC for neurotrophin-3 on the second immunoglobulin-like domain of the Trk receptors" Journal of Biological Chemistry 273(10):5829-5840 (Mar 6, 1998)
- 138 Van de Winkel and Anderson, "Biology of human immunoglobulin G Fc receptors" Journal of Leukocyte Biology 49(5):511-524 (May 1991)
- 139 Vance et al., "Binding of monomeric human IgG defines an expression polymorphism of FcγRIII on large granular lymphocyte/natural killer cells" Journal of Immunology 151(11):6429-6439 (Dec 1, 1993)
- 140 Ward and Ghetie, "The effector functions of immunoglobulins: implications for therapy" Therapeutic Immunology 2(2):77-94 (1995)
- 141 Warmerdam et al., "A single amino acid in the second Ig-like domain of the human Fcγ receptor II is critical for human IgG2 binding" Journal of Immunology 147(4):1338-1343 (Aug 15, 1991)
- 142 Weng et al., "Computational determination of the structure of rat Fc bound to the neonatal Fc receptor" Journal of Molecular Biology 282(2):217-225 (Sep 18, 1998)
- 143 Werther et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1" J. of Immunology 157:4986-4995 (1996)
- 144 Woof et al., "Localisation of the monocyte-binding region on human immunoglobulin G" Molecular Immunology 23(3):319-330 (Mar 1986)
- 145 Wright and Morrison, "Effect of altered C<sub>H</sub>2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1" Journal of Experimental Medicine 180(3):1087-1096 (Sep 1, 1994)
- 146 Wu et al., "A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease" Journal of Clinical Investigation 100(5):1059-1070 (Sep 1, 1997)

Examiner

Dana Saunders

Date Considered

6/7/04

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1726R

Sheet 8 of 8

Serial No.

00713,425

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Presta, L.

Filing Date

15 Nov 2000

Group

53

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- 147 Xu et al., "The N-terminal sequence of the Cq2 domain controls the differential ability of human IgG1 and IgG2 to activate complement" Journal of Immunology (abstract no. 852) 150(8):152A (Apr 15, 1993)
- 148 Yap et al., "Human Fc gamma receptor IIA (FcγRIIA) genotyping and association with systemic lupus erythematosus (SLE) in Chinese and Malays in Malaysia" Lupus 8(4):305-310 (1999)
- 149 Yuan et al., "Antibody-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor functions and IgG subclasses" Journal of Experimental Medicine 187(4):641-648 (Feb 16, 1998)

Examiner

Dana A. Saunders

Date Considered

6/7/04

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

~~AIN 27 2002~~

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1726R1P1

Serial No.

09/713,425

**LIST OF DISCLOSURES CITED BY APPLICANT**

(Use several sheets if necessary)

**Applicant**

Presta, L.

Filing Date

15 Nov 2000

Group

1644

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	162	2003/0158389	21.08.03	Idusogie et al.	530	387.1	

**Examiner**


David Saunders

Date Considered \_\_\_\_\_

6/7/04

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 1



Group  
1644

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	163	2004/0002587	01.01.04	Watkins et al.	530	388.15	

**Date Considered**

6/7/04

USCOMM-DC 80-398.

## U.S. PATENT DOCUMENTS

[illegible]

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.